A new development in fertility treatment scientists have successfully produced early-stage sperm cells from the skin cells of infertile men.

According to the study, Stanford University researchers took skin cells from infertile men, turned them into stem cells known as induced pluripotent stem cellsand then implanted those cells in the tubules of mice testes. (Via Flickr / 7715592@N03,33852688@N08)

Before we move forward, you might be wondering how scientists turned skin cells back into stem cells. This video from Stem Cell Network sums up the process.

"If some adult cell types are taken, grown in plastic dishes and given specific genetic instructions, over time a small number of these cells will reverse from their differentiated state and develop the ability to redifferentiate."(Via Vimeo /Stem Cell Network)

Researchers discovered the stem cells developed into germ cells, the precursor to sperm cells. (Via YouTube / CreekValleyCritters)

But while this new development seemingly bodes well for future fertility treatment, a writer for The Guardian points out one major concern.

"The cells that lodged in the tubules developed into early-stage sperm cells, but others turned into small tumours. The danger of causing cancer in the men is one of the major risks that scientists need to overcome." (Via The Guardian)

And LiveScience reports the research is still in its infancy, noting even though the stem cells produced germ cells, they "did not go on to form mature sperm in the mice."The head researcher for the study told LiveScience this is likely because of the "evolutionary differences between humans and mice."

Despite concerns, Nature World News says this research has potential, because there are various uses for the treatment. "There is also the possibility of using cells from endangered species to help boost their reproduction."

According to the American Society for Reproductive Medicine, about 12 percentof adults suffer from infertility. The study has been published in the journal Cell Reports.

See the original post:
Human skin cells used to create sperm cells

Here is a new development in fertility treatment: Scientists have successfully produced early-stage sperm cells from the skin cells of infertile men.

According to thestudy, Stanford University researchers took skin cells from infertile men, turned them into stem cells known as induced pluripotent stem cells, and then implanted those cells in the tubules of mice testes. (ViaFlickr / 7715592@N03,33852688@N08)

Before we move forward, you might be wondering how scientists turned skin cells back into stem cells. Stem Cell Networksummed up the process: "If some adult cell types are taken, grown in plastic dishes and given specific genetic instructions, over time a small number of these cells will reverse from their differentiated state and develop the ability to redifferentiate."(ViaVimeo /Stem Cell Network)

>> Read more trending stories

Researchers discovered the stem cells developed into germ cells, the precursor to sperm cells. (ViaYouTube /CreekValleyCritters)

But while this new development seemingly bodes well for future fertility treatment, a writer forThe Guardianpoints out one major concern: "The cells that lodged in the (mice) tubules developed into early-stage sperm cells, but others turned into small tumors. The danger of causing cancer in the men is one of the major risks that scientists need to overcome."(ViaThe Guardian)

Despite concerns,Nature World Newssays this research has potential, because there are various uses for the treatment."There is also the possibility of using cells from endangered species to help boost their reproduction," the organization reported.

According to theAmerican Society for Reproductive Medicine, about 12 percentof adults suffer from infertility. The study has been published in the journal Cell Reports.

More:
Scientists use human skin to create sperm cells

Scientists have turned skin tissue from infertile men into early-stage sperm cells in a groundbreaking study that raises hopes for new therapies for the condition.

The unexpected success of the procedure has stunned some scientists, because it was thought to be impossible for the men to make any sperm.

The men who took part in the study had major genetic defects on their Y sex chromosomes, which meant they could not produce healthy adult sperm on their own.

About 1% of men cannot make any sperm, a condition known as azoospermia, while a fifth of men have low sperm counts. Male fertility is a concern for roughly half of couples who seek IVF treatment.

In the latest study, researchers took skin cells from three infertile men and converted them into stem cells, which can grow into almost any tissue in the body. When these cells were transplanted into the testes of mice, they developed into early-stage human sperm cells.

What we found was that cells from men who did not possess sperm at the time of clinical observation were able to produce the precursors for sperm, said Cyril Ramathal, of Stanford University.

Skin cells from infertile men grew into fewer early-stage sperm cells than cells taken from normally fertile men, the study found.

The research is at an early stage, but scientists suspect that the converted skin cells might have grown into mature sperm cells if they had been transplanted into the infertile mens testes.

If further work confirms the suspicion, it may be possible to restore male fertility by taking mens skin cells, turning them into stem cells, and injecting these into their testes. The same might be done for men who are left infertile after having chemotherapy for cancer.

Being able to efficiently convert skin cells into sperm would allow this group to become biologic fathers, said Michael Eisenberg, director of male reproduction and surgery at Stanford, who was not involved in the study. Infertility is one of the most common and devastating complications of cancer treatments, especially for young boys and men.

Read more:
Scientists turn tissue from infertile men into sperm cells

Human embryonic stem cells can become any cell in the body. AFP FILE PHOTO

MANILA, Philippines Health authorities warned the public anew on Saturday about health facilities and medical practitioners offering unauthorized stem cell therapy and products.

In an advisory, the Food and Drug Administration said that to date, not one stem cell or human cells, tissues, and cellular and tissue-based products (HCT/Ps) that applied for registration has been registered by the FDA for compassionate or clinical trial use, or general use.

The use of HCT/Ps without the authorization or permission by the FDA is considered illegal, it said, reminding hospitals and health facilities of the provisions of the FDA Act of 2009, which prohibits the manufacture, use, advertisement or sponsorship of unregistered health products.

This warning extends to all unlicensed practitioners from other countries and to tourists who visit the Philippines for leisure and medical needs, the advisory added.

According to FDA acting director general Kenneth Hartigan Go, the FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of health care procedures.

If health institutions are doing these three procedures, they can continue doing them because those are allowed. Go said, adding that the efficacy of the use of stem cells for the treatment of other diseases, such as diabetes, cancer and autism, among others, has yet to be proven.

Go noted that while many spa centers and salons are advertising stem cell therapy and products, none of them has the approval of the health agency.

As of now we have not accredited any health facility offering stem cell therapy yet, Go said.

Several facilities had applied for accreditation but Go said many of these were asked to correct their deficiencies.

Read this article:
Public warned of fly-by-night stem cell procedures, products

Health authorities on Saturday reissued warnings against health facilities and medical practitioners offering stem-cell therapies or related products, which promise to cure a range of diseases, arrest the aging process or even increase libido.

In an advisory, the Food and Drug Administration stressed that to date not one stem cell or human cells, tissues, and cellular and tissue-based products (HCT/Ps) that applied for registration has been registered by the FDA for compassionate or clinical trial use or for general use.

The use of HCT/Ps without the authorization or permission by the FDA is considered illegal, it said. The agency warned hospitals and health facilities of the provisions of the FDA Act of 2009, which prohibits the manufacture, use, advertisement or sponsorship of unregistered health products.

This warning extends to all unlicensed practitioners from other countries and to tourists who visit the Philippines for leisure and medical needs.

According to FDA acting director general Kenneth Hartigan Go, the FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem-cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of healthcare procedures.

If health institutions are doing these three procedures, they can continue because those are allowed, Go said.

But the efficacy of the use of stem cells for the treatment of other diseases, such as diabetes, cancer and autism, among others, have yet to be proven, he said.

Go noted that while many spa centers and salons are advertising stem-cell therapy treatment and products, none of them have secured the FDAs approval. As of now, we have not accredited any health facility offering stem-cell therapy yet.

Applicants with deficiencies

Read more here:
FDA: No way spas can do stem-cell therapy

PUBLIC RELEASE DATE:

2-May-2014

Contact: Becky Attwood r.attwood@soton.ac.uk 44-023-805-92116 University of Southampton

Gels made from clay could provide an environment that would stimulate stem cells to regenerate damaged tissues such as bone, skin, heart, spinal cord, liver, pancreas and cornea.

Researchers at the University of Southampton believe that clay particles' ability to bind to biological molecules could be used to stimulate the stem cell regeneration process.

Dr Jon Dawson, who is leading the research, explains: "Clay particles encourage molecules to bind to them. This interaction is now routinely harnessed in the design of tablets to carefully control the release and action of a drug. We will use this mechanism to see if we can encourage stem cells to grow new tissue."

The project, funded by a 1.4m grant from the Engineering and Physical Sciences Research Council (EPSRC), aims to create tailormade micro-environments to foster stem cell regeneration. The team will use clay gels both to explore the biological signals necessary to successfully control stem cell behaviour for regeneration and also to provide stem cells with signals to stimulate regeneration in the body.

The approach will first be applied to regenerate bone lost to cancer or hip replacement failure. If successful the same technology may be applied to harness stem cells for the treatment of a whole host of different scenarios, from burn victims to those suffering with diabetes or Parkinson's.

Dr Dawson will be working with Professor Richard Oreffo of the Bone and Joint Research Group at the University of Southampton to explore the application of this technology in orthopaedics. "Fractures and bone loss due to trauma or disease are a significant clinical and socioeconomic problem," Dr Dawson comments. "Clay particles could offer an improved way of stimulating stem cells at the point of injury, which will be better for the patient's recovery."

Dr Dawson believes that the rich electrostatic properties of nano scale clay particles, which are one millionth of a millimetre, could overcome two challenges in the development of stem-cell based regenerative therapies.

The rest is here:
From the dust -- mixing stem cells with clay to regenerate human tissue

Skin cells from infertile men can be turned into the precursors of sperm cells in a lab, according to a new study.

The findings raise the possibility of one day making sperm from the skin cells of men with fertility problems, the researchers said. However, much more research is needed to determine if this is possible and whether it is safe.

In the new study, researchers first transformed the men's skin cells into stem cells, then implanted the cells into the testes of mice where they formed sperm precursor cells. However, one safety issue is that some of the stem cells formed tumors in the mice, said study researcher Renee Reijo Pera, who conducted the work while at Stanford University, and is now a professor of cell biology and neurosciences at Montana State University.

To conduct the study, Pera and colleagues took skin samples from three infertile men, and two fertile men. The infertile men had a genetic mutation in a region of the genome called AZF1 that prevented them from making mature sperm, a condition called azoospermia. [Sexy Swimmers: 7 Facts About Sperm]

The researchers used the skin cells to produce what are called induced pluripotent stem cells (iPS cells), which have the ability to become nearly any tissue type in the body. These iPS cells were then implanted into the testes of mice, where they turned into germ cells, which normally give rise to sperm in males.

However, in the study, the germ cells did not go on to form mature sperm in the mice, likely because of evolutionary differences between humans and mice that blocked the production of such mature cells, Pera said.

The stem cells from fertile men were much better at generating germ cells than those from infertile men. Still, the fact that the infertile men's stem cells produced germ cells at all was surprising, because men with the AZF1 mutation often have no germ cells, Pera said.

The new findings suggest that these infertile men do in fact have the potential to produce germ cells, but the germ cells are lost over time, Pera said. If that's true, young boys with this mutation might be able to preserve their germ cells for the future by collecting and freezing samples of testes tissue, Pera said.

The mouse model used in the study will help researchers better understand the earliest stages of sperm development, Pera said. For example, the cells of human embryo "decide" whether they are going to be germ cells at day 12 after conception, she said. "We've developed a way to study the earliest steps," which take place in the fetus, Pera said.

Previously, the same group of researchers created germ cells from human embryonic stem cells. And last year, experiments in mice showed that skin cells of the animals can be turned into stem cells, which can then be turned into germ cells. When researchers implanted these germ cells in sterile mice, the mice became fertile.

Follow this link:
Skin cells turned into sperm

May 2, 2014 7:02 pm by Stephanie Baum | 0 Comments MedCity News

In the latest stem cell innovation, a group of researchers from Stanford University successfully converted skin cells to stem cells to sperm cells, raising new questions about a potential path to treat infertility. The study was published in Cell Report.

The research used skin samples from five men with a genetic mutation calledazoospermia a genetic mutation that prevented them from making mature sperm.

According to a description of the study on NPRs website, researchers took skin cells from infertile men and transformed them into pluripotent stem cells, which can be converted into any cell in the body. The cells were inserted in mice testes and became immature human sperm cells.

The research is certainly at the early stage and experts caution it will take a lot more research to develop healthy sperm but it is already drawing mixed responses from the research world. Although its been called provocative, Dartmouth bioethicist Ronald Green got particularly dark and called attention to the downside. He speculated that it could lead to thefts of tissue samples or hair from the dead to recreate the dearly departed.

Get our daily newsletter or follow us.

Please enter your email below:

Go here to read the rest:
Stem cell innovation study converts skin cells to sperm cells in potential infertility treatment

April Flowers for redOrbit.com Your Universe Online

A new study, from the Stanford University School of Medicine and Montana State University, demonstrates that, when implanted into the reproductive system of a mouse model, stem cells created from adult, infertile men will yield primordial germ cells. Primordial germ cells normally become sperm cells.

The findings, published in Cell Reports, help to further our understanding of a genetic cause of male infertility and basic sperm biology. The research team says that their approach holds considerable potential for clinical applications.

All of the infertile male participants suffer from a genetic mutation that prevents their bodies from producing mature sperm. The study suggests that the men with this condition called azoospermia might have produced germ cells at some point in their early lives, but these cells were lost as the men matured to adulthood.

Our results are the first to offer an experimental model to study sperm development, said Renee Reijo Pera of the Institute for Stem Cell Biology & Regenerative Medicine and Montana State University. Therefore, there is potential for applications to cell-based therapies in the clinic, for example, for the generation of higher quality and numbers of sperm in a dish.

It might even be possible to transplant stem-cell-derived germ cells directly into the testes of men with problems producing sperm, she added. Considerable study to ensure safety and practicality is needed, however, before reaching that point.

Infertility is a fairly common problem, affecting between 10 and 15 percent of couples in the US. The researchers say that many men are affected by genetic causes of infertility, most commonly due to the spontaneous loss of key genes on the Y sex chromosome. Until now, the causes of infertility at the molecular level have not been clear.

The fact that the research team was able to create primordial germ cells from the infertile men is very promising, but they note that these stem cells created far fewer of these sperm progenitors than the stem cells of men without the genetic mutations. They are sure, however, that this research provides a much needed model to study the earliest steps of human reproduction.

We saw better germ-cell differentiation in this transplantation model than weve ever seen, said Reijo Pera, former director of Stanfords Center for Human Embryonic Stem Cell Research and Education. We were amazed by the efficiency. Our dream is to use this model to make a genetic map of human germ-cell differentiation, including some of the very earliest stages.

Humans share many cellular and physiological processes with common laboratory animals such as mice or fruit flies. In reproduction, however, there are significant variances, making it challenging to recreate the human reproductive processes in a laboratory setting. In addition, many crucial steps, such as the development and migration of primordial germ cells to the gonads,occur in the relatively short first days or weeks after conception.

Read more:
Stem Cells Of Infertile Men Used To Create Preliminary Sperm Cells

By Estel Grace Masangkay

An independent group of scientists led by experts at the New York Stem Cell Foundation Research Institute (NYSCF) reported that they have manufactured the first disease-specific line of embryonic stem cells made with a patients DNA. The achievement is heralded as a major breakthrough in the regenerative medicine field.

This is also the first time cloning technologies have been utilized to generate genetically matched stem cells. The team used somatic cell nuclear transfer to successfully clone a skin cell from a 32 year old female patient with Type 1 diabetes. The cells were transformed into insulin-producing cells similar to lost beta cells in diabetes, which could provide better treatment or even a cure for T1D.

Susan Solomon, CEO and co-founder of NYSCF, says she is excited about the successful production of patient-specific stem cells using somatic cell nuclear transfer (SCNT). CEO Solomon said she became involved with medical research when her son was diagnosed with T1D.

Dr. Egli, scientist from the New York Stem Cell Foundation Research Institute and who led the research, said, From the start, the goal of this work has been to make patient-specific stem cells from an adult human subject with type-1 diabetes that can give rise to the cells lost in the disease. By reprograming cells to a pluripotent state and making beta cells, we are now one step closer to being able to treat diabetic patients with their own insulin-producing cells.

The scientists analyzed factors that affect stem-cell derivation after SCNT. They added histone deacetylase inhibitors and protocol for human oocyte activation, which were crucial in delivering them to the stage at which embryonic stem cells can be properly derived. The beta cells produced from the patients own skin cells are autologous and match the patients DNA. Further research is underway at NYSCF and other institutions for the development of strategies to protect existing and therapeutic beta cells from attacks of the immune system.

The research teams work appeared in the journal Nature.

Go here to read the rest:
Scientists Produce Personalized Stem Cells For Specific Diseases

(PRWEB) May 02, 2014

The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).

Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on report.

This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020.

Download Free PDF Download @ http://www.marketsandmarkets.com/pdfdownload.asp?id=48

The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

Inquire Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48

A number of factors such as the increasing funding from various government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are stimulating the research activities for stem cell therapies. Developing markets, emergence of induced pluripotent stem (iPS) cells as an alternative to embryonic stem cells (ESCs), and evolution of new stem cell therapies represent high growth opportunities for market players.

In 2015, North America will hold the largest share of the global stem cell therapy market. This large share is primarily attributed to the extensive government funding and increasing fast-track approval for stem cell therapeutics by the FDA. Moreover, development of advanced genomic methods for stem cell analysis and high number of ongoing research activities are further fueling the growth of the stem cell therapy market in North America. However, the Asia-Pacific stem cell therapy market is expected to grow at the highest CAGR in the forecast period, owing to factors such as increasing regulatory support through favorable government policies, strong product pipelines, and increasing licensing activities in this region.

Go here to see the original:
Stem Cell Therapy Market (Autologous & Allogeneic) Worth $330 Million in 2020 - New Report by MarketsandMarkets

A new review of previous scientific studies has concluded that stem cell therapy may help reduce the number of deaths in heart patients.

The Cochrane Heart Review Group analyzed data from studies involving just over 1,200 patients in 23 randomized, controlled trials.

The group's report on the potential benefits of stem cell heart repair was published online on April 29 in The Cochrane Library. The Cochrane Reviews are systematic assessments of evidence-based research into human health care and health policy.

There were fewer deaths among heart patients receiving stem cell therapy in addition to standard treatment, compared to patients who were treated with traditional therapies alone or with a placebo. Stem cells are primitive master cells that, under the right conditions, can turn into any cell in the body.

The therapy also reduced the chances that patients, with improved heart function, had to be readmitted to the hospital.

The review noted that stem cell therapy could possibly reduce the number of deaths after one year, but the results of larger clinical trials are needed.

The stem cells are taken from a patients own bone marrow and injected into the hearts of patients with ischemic heart disease and congestive heart failure, repairing damaged cardiac tissue.

Dr. Enca Martin-Rendon, author of the review in Britain, said, This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, Martin-Rendon noted it is difficult to come to any concrete conclusions until larger clinical trials are carried out.

Link:
Stem Therapy May Improve Survival of Heart Patients

New York, NY (PRWEB) May 02, 2014

Stem Cell Institute is releasing additional tickets for its Adult Stem Cell Therapy Clinical Trials seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

After booking its original meeting room beyond capacity, the Stem Cell Institute has reserved a larger room to accommodate additional attendees. The seminar will now take place in the Beekman Room, 2nd Floor, East Corridor of the New York Hilton Midtown.

Those interested in attending are encouraged to register promptly. Only 75 additional seats are available.

Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special guest speaker:

Read more from the original source:
Additional Tickets Released for Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New ...

Spinal cord injury refers the injury to the soft tissues of the spinal cord which is protected by the vertebrae when they are broken or dislocated. The injuries can occur at any level of the spinal cord. The injured segment of the cord and the severity of the damage will determine which body functions are compromised or lost. There has been no cure for it currently. But the symptoms can be treated and some complications can be controlled.

Scientists and doctors turn to stem cells. Stem cells are a class of undifferentiated cells that can differentiate into specialized cell types. Stem cells can repair the damaged cells by the spinal cord injury and also produce some cells to replace the dead cells. A number of published papers and case studies support the feasibility of treating spinal cord injury with allogeneic human stem cells derived from umbilical cord and autologous bone marrow-derived stem cells.

In severe injury, axons are cut or damaged beyond repair, and neural cell membranes are broken. Blood vessels may rupture and cause bleeding into the spinal cords central tissue, or bleeding can occur outside the cord, causing pressure by the blood clot on the cord.

Within minutes, the spinal cord near the site of severe injury swells within the spinal canal. This may increase pressure on the cord and cut blood flow to spinal cord tissue. Blood pressure can drop, sometimes dramatically, as the body loses its ability to self-regulate. All these changes can cause a condition known as spinal shock that can last from several hours to several days.

Some people experienced spinal cord injury may have hemiplegia, loss of many feelings such as touch and hot, and dysfunctions of movement.

After stem cells are transplanted into the damaged segment of the spinal cord, the cells would repair the damaged cells and help them to recover. Also some cells will be produced by stem cells to help improve the damaged functions by spinal cord injury.

See original here:
Spinal Cord Injury Stem Cells | StemcellsHealthCare.com

The future of the University of Minnesotas regenerative medicine research program is looking brighter than ever.

State and federal leaders in the past have denied funding for the Universitys Office of Regenerative Medicine, which includes the Stem Cell Institute, because some had ethical disagreements with stem cell research.

But this legislative session, with a DFL majority and an overall shift in public opinion, researchers and legislators are confident funding will come through this year.

The current House bill sets aside $450,000 for the Office of Regenerative Medicine, while the Senate version outlines a $5 million increase each year from 2015-17. The bills texts dont specify how funds should be used and how they would be divided between the University and the Mayo Clinic, its research partner.

The Senates bill mandates that anadvisory task force comprised of members from the University, the Mayo Clinic and private industry, as well as two other regenerative medicine experts, recommend how to spend the state funding.

Dayton didnt include funds for the research in his original budget proposal this year, but Sen. Terri Bonoff, DFL-Minnetonka, said there seems to be a general consensus among legislators to work together and decide on a funding amount.

I have not heard many naysayers, she said.

Changing perceptions

The state plays a major role in moving the institutes research forward.

These days, legislators are more open to it than they were in the past, said Dr. Andre Terzic, director of the Mayo Clinic Center for Regenerative Medicine.

Read this article:
Legislature could boost U stem cell research

Chaiwat Subprasom/Reuters/Corbis

Many companies around the world offer stem-cell treatments to patients with heart disease.

An analysis of clinical studies that use adult stem cells to treat heart disease has raised questions about the value of a therapy that many consider inappropriately hyped.

Early-phase clinical trials have reported that adult stem cells are effective in treating heart attack and heart failure, and many companies are moving quickly to tap into this potentially lucrative market. But a comprehensive study that looked at discrepancies in trials investigating treatments that use patients own stem cells, published this week in the journal BMJ (ref. 1), finds that only trials containing flaws, such as design or reporting errors, showed positive outcomes. Error-free trials showed no benefit at all.

The publication comes as two major clinical trials designed to conclusively test the treatments efficacy are recruiting thousands of patients.

The BMJ paper is concerning because the therapeutic approach is already being commercialized, argues stem-cell researcher Paolo Bianco at the Sapienza University of Rome. Premature trials can create unrealistic hopes for patients, and divert resources from the necessary basic studies we need to design more appropriate treatments.

Therapies that use adult stem cells typically involve collecting mesenchymal stem cells from bone marrow taken from the patients hip bone. The cells are then injected back into the patient, to help repair damaged tissue. Original claims that they differentiated into replacement cells have been rejected2, and many clinicians now believe that the cells act by releasing molecules that cause inflammation, with an attendant growth of oxygen-delivering small blood vessels, in the damaged tissue.

The approach has spawned international commercialization of various forms of the therapy, with companies offering treatments for disorders ranging from Parkinsons disease to heart failure. But the effectiveness of such therapies remains unproven.

I have a lot of hope for regenerative medicine, but our results make me fearful.

The BMJ study, led by cardiologist Darrel Francis at Imperial College London, examined 133 reports of 49 randomized clinical trials published up to April last year, involving the treatment of patients who had had a heart attack or heart failure. It included all accessible randomized studies, and looked for discrepancies in design, methodology and reporting of results.

Excerpt from:
Doubts over heart stem-cell therapy : Nature News & Comment

Karen Weintraub, Special for USA TODAY 2:49 p.m. EDT April 30, 2014

A study in "Nature" said researchers showed that they could repair damaged hearts by injecting versatile stem cells into macaque monkeys, like this one in Thailand.(Photo: Apichart Weerawong, AP)

Two new studies out today show both the incredible promise of stem cell research and its current limitations.

In one, published in the journal Nature, researchers showed that they could repair damaged hearts by injecting these versatile stem cells into macaque monkeys. Heart disease is the leading cause of death, and if the same process can work in people, it could benefit hundreds of thousands a year.

In the other study, published in Science Translational Medicine, five men were able to regrow leg muscles destroyed by accidents or military service. The researchers, from the University of Pittsburgh, inserted into the men's muscles a "scaffold" of muscle tissue from a pig. Through aggressive physical therapy right after the surgery, the men's own stem cells were encouraged to populate the scaffold and substantially rebuild their leg muscles.

Nothing had been able to help these men before, including multiple surgeries and years of physical therapy, said Stephen Badylak, the study's senior author.

"Frankly, most of these patients have been through hell," he said at a Tuesday news conference.

David Scadden, a physician and co-director of the Harvard Stem Cell Institute, said he was impressed with the rigor and promise of both studies.

It's long been a goal of stem cell research to figure out how to help the body regrow damaged tissue, he said, and both studies mark a significant step toward that goal.

Both studies also showed that stem cells respond to cells around them, he said, with the heart cells learning to beat in sync with the monkey cells and the muscle cells learning to go where they were needed. "Once the cells get to a certain point, it appears they can then follow the lead of their neighbors," he said.

Read the original post:
Stem cells used to repair animal hearts and human muscle

Thanks to a study with monkeys, the idea of using stem cells to accomplish heart repair on a clinical scale seems more realistic. Stem cells have shown promise in small-animal models, that is, in mice and rats. Still, it was unclear whether human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) could be produced in adequate numbers, and cryopreserved with sufficient viability, to even approach human application.

In a step up from small-animal models, scientists at the University of Washington used a monkey model of myocardial infarction to test how well hESC-CMs could replace damaged tissue with new heart cells and restore failing hearts to normal function. The scientists injected 1 billion heart muscle cells derived from hESC-CMs into the infarcted muscle of pigtail macaques (Macaca nemestrina). This was 10 times more of these types of cells than researchers have ever been able to generate before.

The researchers found that over subsequent weeks, the stem-cell derived heart muscle cells infiltrated into the damaged heart tissue, then matured, assembled into muscle fibers, and began to beat in synchrony with the macaque heart cells. After three months, the cells appeared to have fully integrated into the macaque heart muscle.

Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularize damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart, said Charles Murry, M.D., Ph.D., professor of pathology and bioengineering, who led the research team that conducted the experiment.

The research team published its results April 30 in Nature, in an article entitled Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. In this article, the authors indicated that their work demonstrated that hESCs can be grown, differentiated into cardiomyocytes, and cryopreserved at a scale sufficient to treat a large-animal model of myocardial infarction.

With further refinements in manufacturing, the scale up to trials in human patients seems feasible, the researchers wrote. Large-animal models are important forerunners to human trials, because they impart real-world rigor to issues such as cell production, delivery, and end-point analyses, while permitting mechanistic studies not possible in patients.

On average, the transplanted stem cells regenerated 40% of the damaged heart tissue. Ultrasound studies of the macaques hearts showed that the ejection fraction, an indication of the hearts ability to pump blood, improved in some of the treated animals but not all. The researchers also found that arteries and veins from the macaques hearts grew into the new heart tissue, the first time it has been shown that blood vessels from a host animal will grow into and nurture a large stem-cell derived graft of this type.

The most concerning complications were arrhythmias that occurred in the weeks after the macaques received the stem cell injections, Dr. Murry said. None of the macaques, however, appeared to have symptoms during these episodes, which disappeared after two to three weeks as the stem cells matured and became more electrically stable.

The researchers also cautioned that in their macaque model, the infarcts they had induced were smaller than the clinically severe infarcts that might benefit most from hESC-CM therapy. The researchers added that larger infarcts, in human hearts, might manifest more arrhythmias.

Because ventricular arrhythmias can be life threatening, they need to be understood mechanistically and managed en route to safe clinical translation, the authors noted. Nevertheless, the extent of remuscularization and electromechanical coupling seen here encourages further development of human cardiomyocyte transplantation as a clinical therapy for heart failure.

Follow this link:
GEN | News Highlights:Human Stem Cells Repair Heart Damage ...

Image Caption: This image shows an implanted graft of cardiac cells derived from human stem cells (green) meshed and beat with primates' heart cells (red). Credit: Murry Lab/University of Washington

April Flowers for redOrbit.com Your Universe Online

When a heart attack occurs, the oxygen-rich blood that normally flows through is interrupted by the blockage in an artery. The longer that blood flow is restricted or cut off, the more tissue and muscle in the area dies or is scarred. The eventual result can be heart failure, especially if one heart attack is followed by another.

In 2013, Harvard Health Publications released a report taking a look at the state of stem cell research into the problem of regenerating heart tissue, and the results were mixed.

A new study from the University of Washington, however, reveals improvement in those results. The findings, published online in Nature, demonstrate that damaged heart muscles in monkeys have been restored by the use of heart cells created from human embryonic stem cells. The exciting implication, according to the research team, is that their approach should also be feasible in humans.

Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularize damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart, said Dr. Charles Murry, UW professor of pathology and bioengineering and director of the UW Center for Cardiovascular Biology, in a recent statement.

Murray, who collaborated with Dr. Michael Laflamme and other colleagues at the UW Institute for Stem Cell & Regenerative Medicine, predicts clinical trials with humans within the next four years.

[ Watch the Video: Regenerating Heart Muscle Damage With Stem Cell Therapy ]

For the study, the researchers induced controlled myocardial infarctions, a type of heart attack, in anesthetized pigtail macaques, by blocking the coronary artery for 90 minutes. This is the accepted practice for studying myocardial infarction in primates.

Coronary artery disease is the primary culprit in myocardial infarctions in humans. The infarcted heart muscle, damaged by a lack of oxygen, does not grow back, leaving the heart less able to pump blood. This often leads to heart failure, the leading cause of cardiovascular death. Researchers hope to use new heart cells created from stem cells in order to restore normal function to the failing heart.

Read the original here:
Heart Muscles Repaired After Heart Attack Using Human Embryonic Stem Cells

It shows for the first time that we can do regeneration at a scale that the world has never seen before, said Dr Charles Murry, professor of pathology and bioengineering, at the University of Washington.

"Before this study, it was not known if it is possible to produce sufficient numbers of these cells and use them to re-muscularise damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart."

Weve shown that (stem cells) will survive and they will organise to form new heart muscle and they will connect with the surrounding cardiac muscle cells and beat in synchrony.

The green area shows the regenerated heart muscle

Currently heart muscle cannot be repaired and people with severe heart failure must wait for a heart transplant.

In the study the team induced heart attacks, in anesthetised macaque monkeys.

Over the course of two weeks they injected one billion heart muscle cells derived from human embryonic stem cells.

The researchers found that the stem cells infiltrated into the damaged heart tissue, matured, and knitted into muscle fibers, before beginning to beat in rhythm with the macaque heart cells.

After three months, the cells had fully integrated into the heart. On average the transplanted stem cells regenerated 40 percent of the damaged heart tissue and improve the ability of the heart to pump blood.

Although the study has been carried out on macaque monkeys, the researchers at the University of Washington said "the approach should be feasible in humans".

Originally posted here:
Stem cell injections may take place of heart swaps